Novadaq Technologies Inc.TSX: NDQ

Novadaq's SPY System highlighted at STS' Annual Meeting Symposium

· Issued by Novadaq Technologies Inc. via CNW
Growing Awareness of SPY Benefits Leads to Increased Adoption

TORONTO, Jan. 31 /CNW/ - Novadaq(R) Technologies, Inc. (TSX: NDQ), a
developer of medical imaging systems, today announced that its SPY(R)    
Intra-operative Imaging System was the topic of a continuing medical education
evening symposium at the 2006 Society of Thoracic Surgeons (STS) Meeting. The
symposium, entitled Intra-operative Imaging: Changing Perspectives in Coronary
Bypass Surgery, was held last night at the Hilton Chicago hotel. During the
STS Meeting, Novadaq also announced that they increased their install base to
26 SPY Systems in the United States.
"The subject of intra-operative imaging for this symposium was quite
timely and from a quality standpoint, very important," said Dr. T. Bruce
Ferguson Jr., MD, Associate Chief of Cardiothoracic and Vascular Surgery, and
Director of Quality and Performance in the Department of Surgery at the Brody
School of Medicine at East Carolina University. "It has set the stage for a
thorough re-examination and re-evaluation of traditional concepts and current
practices of coronary artery bypass graft surgery by all cardiac surgeons
going forward."
"The Society of Thoracic Surgeons is an extremely important audience for
us and for SPY. This event has helped us to raise our profile and increase
product awareness with this influential group," said Dr. Arun Menawat,
President and Chief Executive Officer of Novadaq Technologies Inc. "The
benefits of SPY presented at the symposium are enabling us to update the
standard of care and drive SPY adoption."
Faculty for the program included well known cardiac surgeons: Bruce W.
Lytle, MD from the Cleveland Clinic Foundation; Dr. T. Bruce Ferguson Jr., MD
from East Carolina University; David P. Taggart, MD, PhD from Oxford
University; and Stephen E. Fremes, MD from Sunnybrook and Women's College
Health Sciences Centre, joined by Course Director Michael J. Mack, MD from
Medical City Dallas Hospital. Topics discussed included current challenges in
cardiac surgery related to graft durability, intra-operative graft patency
assessment, long-term experiences with SPY imaging, comparisons to other
methods of graft assessment and the role of intra-operative imaging as a
standard of care.

About Novadaq Technologies

Novadaq Technologies (TSX: NDQ) develops and commercializes medical
devices based on its proprietary imaging platform for the diagnosis and
treatment of human vascular and ophthalmic diseases and conditions. Novadaq's
SPY Intra-operative Imaging System, commercially available worldwide, enables
cardiac surgeons to visually assess coronary vasculature and bypass graft
functionality during the course of open-heart bypass surgery. Novadaq's
ophthalmic product, the OPTTX(TM) System, is aimed at the diagnosis,
evaluation and treatment of wet Age-related Macular Degeneration (AMD) by
using the same core imaging technology that is used in the SPY System. The
OPTTX System is currently being evaluated in clinical trials.
For more information, please visit the company's website at
www.novadaq.com.

Certain statements included in this press release may be considered
forward-looking. Such statements involve known and unknown risks,
uncertainties and other factors that may cause actual results, performance or
achievements to be materially different from those implied by such statements,
and therefore these statements should not be read as guarantees of future
performance or results. All forward-looking statements are based on Novadaq's
current beliefs as well as assumptions made by and information currently
available to Novadaq and relate to, among other things, anticipated financial
performance, business prospects, strategies, regulatory developments, market
acceptance and future commitments. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the date
of this press release. Due to risks and uncertainties, including the risks and
uncertainties identified by Novadaq in its public securities filings; actual
events may differ materially from current expectations. Novadaq disclaims any
intention or obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.

%SEDAR: 00022069E

Novadaq Technologies Inc. on 6ix

Story so far

Earlier from Novadaq Technologies

Later from Novadaq Technologies

All Novadaq Technologies news releases